precision engineered l-carnitine 500mg L-Carnitine500®, 500 mg, 120 Capsules L-Carnitine, 500 mg, 120 Capsules

It has been elucidated that ROS not only contribute to the reduction of NO bioavailability (Lagoda et al., 2007)

The OCTN2 carnitine transporter mediates high-affinity carnitine transport Defective OCTN2 activity reduces carnitine levels and impairs fatty acid oxidation Missense mutations in OCTN2 define the function of selected transporter domains Defects in carnitine biosynthesis do not reduce carnitine levels Acknowledgments This work was supported in part by NIH grant DK 53824

This medication is not made for resale, bulk distribution, or office use, and is compounded exclusively to meet the clinical needs of individual patients when commercially available alternatives are not appropriate

Alternative treatment for the underlying medical condition should be initiated as clinically indicated [see Warnings and Precautions (5.3)]

Data availability Data described in the manuscript, code book, and analytic code will be available by submitting a request to the corresponding author

We have decided to publish this experience in spite of its limited size, as we think the outcomes achieved with our multimodal therapy with combined antioxidants in these patients may prove useful in urology and andrology practice, and we would welcome randomized controlled studies being carried out in the future to investigate the effectiveness of this treatment in a larger number of PD patients